Reduced dose of polio vaccine feasible in low-income areas

Vaccinating infants with a single fractional dose of inactivated poliovirus (IPV) is an effective and more affordable alternative to using multiple full doses, report researchers in the New England Journal of Medicine.

"Vaccinating infants with a single fractional dose of IPV can induce priming and seroconversion in more than 90% of immunized infants," say Roland Sutter (World Health Organization, Geneva, Switzerland) and colleagues.

In a clinical trial conducted at 13 vaccination sites in Cuba, 310 infants were randomly allocated to receive either a fractional dose of IPV (one fifth of the full dose) or a full dose at age 4 and 8 months. Fractional doses were administered intradermally and full doses intramuscularly.

After the first dose of IPV, antibodies to poliovirus types 1, 2, and 3 developed in 16.6%, 47.1%, and 14.7% of the fractional dose group, respectively, and in 46.6%, 62.8%, and 32.0% of the full-dose group.

A priming response to poliovirus type 1, 2, and 3 was met in 90.8%, 94.0%, and 89.6% of the fractional dose group and in 97.6%, 98.3%, and 98.1% of the full-dose group, respectively.

After the second dose of IPV, the cumulative rates of seroconversion to poliovirus types 1, 2, and 3 were 93.6%, 98.1%, and 93.0% in the fractional dose group and 100%, 100%, and 99.4% in the full-dose group, respectively.

There were 114 adverse events in the fractional dose group and 11 in the full-dose group. However, these were classified as minor, with the most common ones redness at the injection site, induration at the injection site, and raised temperature.

The team says two fractional doses of IPV administered on an appropriate schedule, with the first dose not administered before the age of 2 months, and at least 2 months between doses, would reduce the cost of each vaccination from the current price of US$ 6.00 (€ 4.40) to US$ 1.20 (€ 0.88). Furthermore, a one-dose IPV priming schedule could further reduce the cost to 60 cents (€ 0.44).

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2018, August 23). Reduced dose of polio vaccine feasible in low-income areas. News-Medical. Retrieved on December 24, 2024 from https://www.news-medical.net/news/20130204/Reduced-dose-of-polio-vaccine-feasible-in-low-income-areas.aspx.

  • MLA

    Robertson, Sally. "Reduced dose of polio vaccine feasible in low-income areas". News-Medical. 24 December 2024. <https://www.news-medical.net/news/20130204/Reduced-dose-of-polio-vaccine-feasible-in-low-income-areas.aspx>.

  • Chicago

    Robertson, Sally. "Reduced dose of polio vaccine feasible in low-income areas". News-Medical. https://www.news-medical.net/news/20130204/Reduced-dose-of-polio-vaccine-feasible-in-low-income-areas.aspx. (accessed December 24, 2024).

  • Harvard

    Robertson, Sally. 2018. Reduced dose of polio vaccine feasible in low-income areas. News-Medical, viewed 24 December 2024, https://www.news-medical.net/news/20130204/Reduced-dose-of-polio-vaccine-feasible-in-low-income-areas.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research suggests no need for yellow fever vaccine booster after initial dose